Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology

Sara Sheikhbahaei; Esther Mena; Puskar Pattanayak; Mehdi Taghipour; Lilja B Solnes; Rathan M Subramaniam

doi:10.1016/j.cpet.2016.08.002

Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology

PET Clin. 2017 Jan;12(1):105-118. doi: 10.1016/j.cpet.2016.08.002. Epub 2016 Oct 5.

Authors

Sara Sheikhbahaei¹, Esther Mena¹, Puskar Pattanayak¹, Mehdi Taghipour¹, Lilja B Solnes¹, Rathan M Subramaniam²

Affiliations

¹ Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA.
² Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA; Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of Clinical Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Advanced Imaging Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address: rathan.subramaniam@UTsouthwestern.edu.

PMID: 27863562
DOI: 10.1016/j.cpet.2016.08.002

Abstract

A variety of methods have been developed to assess tumor response to therapy. Standardized qualitative criteria based on 18F-fluoro-deoxyglucose PET/computed tomography have been proposed to evaluate the treatment effectiveness in specific cancers and these allow more accurate therapy response assessment and survival prognostication. Multiple studies have addressed the utility of the volumetric PET biomarkers as prognostic indicators but there is no consensus about the preferred segmentation methodology for these metrics. Heterogeneous intratumoral uptake was proposed as a novel PET metric for therapy response assessment. PET imaging techniques will be used to study the biological behavior of cancers during therapy.

Keywords: Molecular imaging; Oncology; PET/computed tomography; Precision medicine; Therapy response.

Publication types

Review

MeSH terms

Biomarkers, Tumor
Fluorodeoxyglucose F18
Humans
Molecular Imaging*
Molecular Targeted Therapy
Neoplasms / diagnostic imaging*
Neoplasms / therapy*
Outcome Assessment, Health Care
Positron Emission Tomography Computed Tomography*
Precision Medicine*
Predictive Value of Tests
Prognosis
Radiopharmaceuticals

Substances

Biomarkers, Tumor
Radiopharmaceuticals
Fluorodeoxyglucose F18